Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.05B
Enterprise ValueAU$1.89K
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding599,638,850
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$22.27M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA low debt-to-equity profile reduces refinancing and interest-rate risk, giving management financial flexibility to fund clinical commercialization and iterative product development. Over 2-6 months this supports execution without immediate capital stress, aiding durability despite negative earnings.
Proprietary XV Imaging PlatformOwning a specialized CT-based XV imaging and analytics platform is a structural competitive advantage in respiratory diagnostics. Software-driven functional lung mapping creates clinical differentiation and recurring adoption potential through integration with provider workflows, supporting medium-term commercial traction.
Improving Free Cash Flow TrendAn improving free cash flow trajectory, even from negative levels, signals progress on operational cash conversion and cost discipline. This trend can extend runway and reduce near-term external funding needs, strengthening the company’s ability to pursue commercialization over the coming months.
Bears Say
Declining RevenueFalling top-line undermines scale economics essential for SaaS-like medical software margins and recurring sales. Over a 2-6 month horizon, continued revenue contraction suggests challenges in clinical adoption or sales execution, making margin recovery and profitable scaling materially harder.
Negative Operating & Free Cash FlowSustained negative operating and free cash flows force reliance on external financing, which can constrain strategic investments and slow commercialization. Persisting cash burn over months elevates liquidity risk and may limit ability to expand sales, support customers, or fund regulatory and market initiatives.
Persistent Losses And Negative ROEOngoing net losses and negative ROE erode shareholder capital and limit self-funded growth. Without sustained margin improvement or significant revenue inflection, profitability remains out of reach, jeopardizing medium-term viability and the ability to reinvest earnings into commercialization and R&D.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.05B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 35 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 599,638,850 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$4.97 (-14.95% Downside)
AU$4.97 (-14.95% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 94%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$100.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.97
▼(-14.95% Downside)
Technical Analysis
Compumedics Limited
―
Somnomed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―